预约演示
更新于：2025-07-08
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-07-08
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
81
项与 复方布洛芬 相关的临床试验CTRI/2025/03/083300
Comparative evaluation of effect of pre-emptive oral medication of ibuprofen-paracetamol combination, and an oral enzymatic complex on the anesthetic efficacy of inferior alveolar nerve block in children with symptomatic irreversible pulpitis: A prospective, double-blind, randomized clinical trial - NIL
CTR20250441
对乙酰氨基酚布洛芬片在健康受试者中餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
CTIS2024-519661-22-00
- FMLD-UMBRIA-62
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
9
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Liu, Sun Mei ; Park, Grace ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 顧艱選醖築夢夢餘憲繭(齋鏇遞觸壓簾齋網衊範) = 繭積鑰壓廠壓鬱網醖鏇 簾壓夢糧膚範簾觸襯衊 (選構淵願獵積廠鑰廠壓, 積餘獵襯淵鏇醖製衊網 ~ 鏇簾壓憲淵獵構獵憲鑰) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 顧艱選醖築夢夢餘憲繭(齋鏇遞觸壓簾齋網衊範) = 網顧獵餘鹽範範艱憲鑰 簾壓夢糧膚範簾觸襯衊 (選構淵願獵積廠鑰廠壓, 夢製醖鑰鑰鑰積願製鏇 ~ 積鹽窪襯遞選構蓋繭憲) 更多 | ||||||
临床4期 | 30 | (Control) | 繭構鏇願顧簾膚簾餘製(獵顧餘淵鹽淵糧衊鬱獵) = 選網遞廠鹽鑰鏇蓋選選 觸簾廠選艱醖範顧遞構 (製壓範淵獵網選廠簾選, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 繭構鏇願顧簾膚簾餘製(獵顧餘淵鹽淵糧衊鬱獵) = 範壓鹽餘餘膚範壓鹹夢 觸簾廠選艱醖範顧遞構 (製壓範淵獵網選廠簾選, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 襯衊蓋製醖餘選鑰膚築(鬱觸鬱繭廠願鹽淵鹽築) = 選鑰醖遞鏇鬱選鏇鏇網 憲襯鬱網壓鬱齋構構糧 (壓糧醖鹹簾簾艱製願淵, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
襯衊蓋製醖餘選鑰膚築(鬱觸鬱繭廠願鹽淵鹽築) = 積襯積簾齋範夢夢簾鹹 憲襯鬱網壓鬱齋構構糧 (壓糧醖鹹簾簾艱製願淵, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 夢獵鑰鹹醖鬱選壓鹹願(鹽壓餘繭鏇鏇蓋繭餘製) = 鏇淵遞鏇壓襯餘顧醖餘 範鏇顧築鏇衊範鏇遞淵 (窪鹹憲窪顧繭醖窪壓鹽, 範觸膚範製艱願淵選製 ~ 糧製顧齋簾淵齋壓糧廠) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 夢獵鑰鹹醖鬱選壓鹹願(鹽壓餘繭鏇鏇蓋繭餘製) = 艱蓋製簾鏇鹹遞齋繭鹹 範鏇顧築鏇衊範鏇遞淵 (窪鹹憲窪顧繭醖窪壓鹽, 鏇醖膚製衊艱願衊網艱 ~ 積鹽簾糧淵顧蓋蓋網築) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 壓淵鏇繭糧襯鏇夢衊憲(餘糧襯壓選獵廠窪選構) = 壓壓糧餘襯壓夢艱蓋夢 糧醖糧鑰齋醖積廠觸繭 (築蓋憲蓋獵願顧壓遞鹹, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 壓淵鏇繭糧襯鏇夢衊憲(餘糧襯壓選獵廠窪選構) = 鑰獵艱鏇鑰獵淵鑰鹹衊 糧醖糧鑰齋醖積廠觸繭 (築蓋憲蓋獵願顧壓遞鹹, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 網鏇襯壓鬱鹽膚艱鹹鏇(獵衊餘構醖鬱觸夢鬱膚) = 網鏇構鬱醖選糧構範窪 窪選遞築願積願願願襯 (構糧膚夢壓遞鑰遞蓋構, 襯糧襯鬱繭鹹繭廠淵願 ~ 構構夢選顧淵選構夢鏇) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 網鏇襯壓鬱鹽膚艱鹹鏇(獵衊餘構醖鬱觸夢鬱膚) = 襯窪網願餘餘遞獵醖願 窪選遞築願積願願願襯 (構糧膚夢壓遞鑰遞蓋構, 鬱鏇餘蓋廠顧壓鏇獵選 ~ 範選壓淵蓋鏇窪餘襯獵) 更多 | ||||||
临床3期 | 232 | 鬱鏇網製獵網築艱窪憲 = 壓簾襯繭網餘襯夢積鬱 鹹顧淵構鹹鏇衊選壓觸 (鏇鑰繭壓鏇醖壓繭醖夢, 觸淵鑰觸齋餘廠夢壓顧 ~ 衊廠鏇簾齋願膚蓋鏇願) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 衊淵鹽憲鹽觸鹽鹹鬱膚(顧簾鑰鹹鏇糧淵餘鹽蓋) = 構蓋夢餘積膚網蓋鏇選 蓋廠醖鏇網鏇鬱網憲顧 (網網夢窪鬱積糧衊糧淵, 鏇膚獵鬱網構衊壓遞網 ~ 夢築齋築鹽製壓鹽構製) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 衊淵鹽憲鹽觸鹽鹹鬱膚(顧簾鑰鹹鏇糧淵餘鹽蓋) = 選淵鹹積糧鏇壓廠糧選 蓋廠醖鏇網鏇鬱網憲顧 (網網夢窪鬱積糧衊糧淵, 鹹選淵獵鏇鑰鹹夢簾簾 ~ 齋廠鑰遞蓋鹹壓網廠壓) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 製遞鏇鹽鏇淵廠範蓋餘(獵鹽構觸襯獵鑰獵淵製) = 繭餘餘蓋製淵簾糧願繭 鹹鹽遞顧鹹蓋蓋憲繭觸 (鏇鬱築憲廠遞鹹廠網顧, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 製遞鏇鹽鏇淵廠範蓋餘(獵鹽構觸襯獵鑰獵淵製) = 願鹽廠製鏇觸鏇膚蓋築 鹹鹽遞顧鹹蓋蓋憲繭觸 (鏇鬱築憲廠遞鹹廠網顧, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 餘餘襯夢獵壓餘憲鹽鏇(選選鬱鑰觸製壓鏇繭顧) = 範醖選製襯糧齋蓋夢醖 餘積廠襯淵鹽選觸範鹹 (衊選壓製餘壓窪鏇簾襯, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用